Bellerophon Therapeutics, Inc. (BLPH): Jonathan M Peacock , CEO of Bellerophon Therapeutics, Inc. purchased 5,000 shares on May 17, 2016. The Insider buying transaction was reported by the company on May 18, 2016 to the Securities and Exchange Commission. The shares were purchased at $1.37 per share for a total value of $6,841.50 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on Dec 17, 2015, Jonathan M Peacock (CEO) purchased 20,300 shares at $2.74 per share price.On May 22, 2015, Martin Meglasson (Chief Scientific Officer) purchased 712 shares at $8.40 per share price.Also, On Feb 24, 2015, North America, Inc. Linde (10% owner) purchased 358,916 shares at $12.00 per share price.On Feb 24, 2015, Matthew S. Holt (director 10% owner) purchased 1,070,166 shares at $12.00 per share price.
Shares of Bellerophon Therapeutics Inc (BLPH) ended Thursday, May 19, 2016 session in red amid volatile trading. The shares closed down -0.09 points or -6.67% at $1.26 with 30,298 shares getting traded. Post opening the session at $1.2501, the shares hit an intraday low of $1.21 and an intraday high of $1.3548 and the price vacillated in this range throughout the day. The company has a market cap of $16,979 M and the number of outstanding shares has been calculated to be 13,47,50,00,000 shares. The 52-week high of Bellerophon Therapeutics Inc is $9.72 and the 52-week low is $1.2.
Company has been under the radar of several Street Analysts.Bellerophon Therapeutics Inc is Reiterated by Leerink Partners to Outperform while Lowering the Price Target of the company shares to $ 9 from a previous price target of $11 . The Rating was issued on Mar 22, 2016.
Bellerophon Therapeutics Inc. is a clinical-stage therapeutics company. The Company is focused on developing products at the intersection of drugs and devices that address medical needs in the treatment of cardiopulmonary and cardiac diseases. The Company has two programs in development. The first program INOpulse is based on its pulsatile nitric oxide delivery device. The Company is developing two product candidates under its INOpulse program: one for the treatment of pulmonary arterial hypertension (PAH) and the other for the treatment of pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD) which is in Phase II development. Its second program is bio absorbable cardiac matrix (BCM) which is in a placebo-controlled clinical trial. The Company is developing BCM for the prevention of cardiac remodeling which leads to congestive heart failure following an ST-segment elevated myocardial infarction (STEMI).